GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Cyclically Adjusted PB Ratio

AIM ImmunoTech (STU:HXB2) Cyclically Adjusted PB Ratio : 0.02 (As of May. 28, 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Cyclically Adjusted PB Ratio?

As of today (2024-05-28), AIM ImmunoTech's current share price is €0.344. AIM ImmunoTech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €20.30. AIM ImmunoTech's Cyclically Adjusted PB Ratio for today is 0.02.

The historical rank and industry rank for AIM ImmunoTech's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:HXB2' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.09   Max: 1.48
Current: 0.02

During the past years, AIM ImmunoTech's highest Cyclically Adjusted PB Ratio was 1.48. The lowest was 0.01. And the median was 0.09.

STU:HXB2's Cyclically Adjusted PB Ratio is ranked better than
97.09% of 654 companies
in the Biotechnology industry
Industry Median: 1.73 vs STU:HXB2: 0.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AIM ImmunoTech's adjusted book value per share data for the three months ended in Mar. 2024 was €0.076. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €20.30 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AIM ImmunoTech Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AIM ImmunoTech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Cyclically Adjusted PB Ratio Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.03 0.02 0.01 0.02

AIM ImmunoTech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.02 0.02 0.02

Competitive Comparison of AIM ImmunoTech's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, AIM ImmunoTech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Cyclically Adjusted PB Ratio falls into.



AIM ImmunoTech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AIM ImmunoTech's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.344/20.3
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AIM ImmunoTech's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.076/131.7762*131.7762
=0.076

Current CPI (Mar. 2024) = 131.7762.

AIM ImmunoTech Quarterly Data

Book Value per Share CPI Adj_Book
201406 60.227 100.560 78.923
201409 55.766 100.428 73.173
201412 52.483 99.070 69.810
201503 58.288 99.621 77.102
201506 51.293 100.684 67.133
201509 44.031 100.392 57.796
201512 39.886 99.792 52.670
201603 35.254 100.470 46.239
201606 33.028 101.688 42.801
201609 27.048 101.861 34.992
201612 26.710 101.863 34.554
201703 20.341 102.862 26.059
201706 13.972 103.349 17.815
201709 11.927 104.136 15.093
201712 9.840 104.011 12.467
201803 9.280 105.290 11.614
201806 7.317 106.317 9.069
201809 5.063 106.507 6.264
201812 4.106 105.998 5.105
201903 0.874 107.251 1.074
201906 2.128 108.070 2.595
201909 1.945 108.329 2.366
201912 1.097 108.420 1.333
202003 1.108 108.902 1.341
202006 1.199 108.767 1.453
202009 1.260 109.815 1.512
202012 1.181 109.897 1.416
202103 1.234 111.754 1.455
202106 1.125 114.631 1.293
202109 1.089 115.734 1.240
202112 1.036 117.630 1.161
202203 0.995 121.301 1.081
202206 0.946 125.017 0.997
202209 0.882 125.227 0.928
202212 0.742 125.222 0.781
202303 0.662 127.348 0.685
202306 0.561 128.729 0.574
202309 0.421 129.860 0.427
202312 0.178 129.419 0.181
202403 0.076 131.776 0.076

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AIM ImmunoTech  (STU:HXB2) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AIM ImmunoTech Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (STU:HXB2) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines